Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia
09 Novembre 2021 - 1:00PM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
eye care, nasal care, oral care, dermatological conditions and
disinfectant use, and its long-time partner, Dyamed Biotech Pte
Ltd., announce a renewed and expanded long-term partnership for
Singapore, Malaysia, Indonesia and Thailand for multiple
indications using Sonoma’s patented Microcyn® Technology.
Dyamed Biotech Pte Ltd., one of Sonoma’s first international
partners, successfully commercializes Dermacyn® Wound Care,
Dermacyn® Scarless for Scar Reduction, and Dermacyn® Ezyma Spray
for itch relief associated with atopic dermatitis. Dyamed expects
to launch Ocucyn® Eye Care and Oracyn® Oral Care in 2022. The
Dermacyn® line of products are widely used at many hospitals
throughout Singapore and Malaysia.
“We are so pleased with the performance of the Dermacyn® line of
products which have helped provide modern wound care for both acute
and chronic wounds in our hospitals and health care facilities for
many years. With the additional indications using the patented
Microcyn® Technology for scar reduction and atopic dermatitis
treatment, we have had many patients see positive results,” said
Dyamed Biotech Pte Ltd., CEO Theodore Tan.
“In addition, we look forward to the next year as we expand the
Dermacyn® line of products for both eye and oral care in pharmacies
and hospitals throughout Southeast Asia,” Mr. Tan added.
Bruce Thornton, Chief Operating Officer of Sonoma
Pharmaceuticals said, “Dyamed has been a valued partner since 2004
and we are excited to support the next chapter of this special
partnership. With the addition of the new territories of Indonesia
and Thailand and new oral and eye care products, we expect Dyamed
to expand its reach into both hospitals and pharmacy care. We are
continuously seeking to expand our network of international
distributors with quality partners like Dyamed to increase the
reach of Sonoma products worldwide.”
About Dyamed Biotech Pte Ltd.,
Dyamed Biotech was established in 1998 to distribute quality
medical diagnostic devices in Southeast Asia. The company is
headquartered in Singapore and has a branch office in Malaysia.
Dyamed Biotech distributes to public and private hospitals, clinics
and pharmacies in Southeast Asia. Please contact us at +65 6848
1028 or visit our website at www.dyamed.com.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care, disinfectant
use and dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 54 countries worldwide and the company
actively seeks new distribution partners. The company’s principal
office is in Woodstock, Georgia, with manufacturing operations in
Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.sonomapharma.com. For partnership opportunities, please contact
busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “develop” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that
regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical
results may not be replicated in actual patient settings,
protection offered by the company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors,
the available market for the company’s products will not be as
large as expected, the company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the company’s cash needs, fund further
development, as well as uncertainties relative to the COVID-19
pandemic and economic development, varying product formulations and
a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the company’s filings with the Securities and
Exchange Commission. The company disclaims any obligation to update
these forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211109005550/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024